Carboplatin (CBDCA) and bevacizumab (BEV) are active in glioblastoma (GBM) with different profiles of toxicity. To date, no study has compared the value of the addition of BEV to historical or traditional cytotoxic chemotherapy. We sought to determine the relative value of BEV in combination with CBDCA versus CBDCA alone in patients with recurrent GBM.
Eligible patients with progressive GBM following surgery, radiotherapy and temozolomide received CBDCA either alone (group 1, n = 25) or in combination with BEV (group 2, n = 23) at 5 mg/kg once every 3 weeks between June 2010 and December 2013. Baseline characteristics and outcomes after treatment were recorded. The primary end points of this retrospective analysis were progression-free survival (PFS) and objective response rate. Secondary end points included safety and overall survival (OS).
Forty-eight patients were enrolled. The median number of cycles was 4 in group 1 and 6 in group 2. No toxicities or intracerebral bleeding were observed. The objective response rate was higher in group 2 than group 1, 66% vs 24% (p = 0.003). The estimated median PFS and OS were 3.1 vs 6.7 months (p<0.0001) and 6.1 vs 8.6 months (p = 0.09) in group 1 vs group 2, respectively.
The combination of BEV and CBDCA is associated with improved response rates and survival compared with CBDCA alone. These results highlight the value of BEV in recurrent GBM. However, the clinical benefit of this interesting approach needs validation in a larger patient cohort.
Tumori 2015; 101(1): 41 - 45
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsGentian Kaloshi, Pavllo Diamandi, Bujar Cakani, Gramoz Brace, Arben Rroji, Mentor Petrela
- • Accepted on 28/07/2014
- • Available online on 11/02/2015
- • Published in print on 20/03/2015
This article is available as full text PDF.
- Kaloshi, Gentian [PubMed] [Google Scholar] , * Corresponding Author (firstname.lastname@example.org)
- Diamandi, Pavllo [PubMed] [Google Scholar]
- Cakani, Bujar [PubMed] [Google Scholar]
- Brace, Gramoz [PubMed] [Google Scholar]
- Rroji, Arben [PubMed] [Google Scholar]
- Petrela, Mentor [PubMed] [Google Scholar]
Department of Neurosurgery, University Hospital Center “Mother Theresa”, Tirana - Albania
Dr G. Kaloshi and Dr P. Djamandi contributed equally to this work.